Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections

E. Jauregui, L.; Babazadeh, S.; Seltzer, Elyse; Goldberg, L.; Krieviņš, Dainis; J. Frederick, Mitchell; Krause, David; Satilovs, I.; Endzinas, Žilvinas; Breaux, J.; O'Riordan, W.

doi:10.1086/497271

Public

Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections

Published in Clinical Infectious Diseases • Oct 19, 2005

Authors:

L. E. Jauregui

S. Babazadeh

Elyse Seltzer

Abstract

BACKGROUND: Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The efficacy of dalbavancin for treatment of skin and skin structure infections (SSSIs) ...

Subject

Dalbavancin

Medicine

Linezolid

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!